

Midazolam

Potential SALAD								
Ensure selection of the correct strength of midazolam ampoule								
CAUTION: High Administration Risk Rating								
Form	10mg per 5mL ampoule (2 mg/mL) 10mg per 2mL ampoule (5 mg/mL)	Store at room temperature in outer box for light protection.						
Reconstitution	Already in solution <ul style="list-style-type: none">• Draw up using a 5 micron filter needle• Use gloves when opening ampoules							
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%							
Administration	IV Injection							
	Administer at a rate of 2mg/min.							
	IV Infusion - ITU & ED only							
	Administer using a syringe driver to control the rate of infusion. Titrate dose to desired effect. To prepare a 2mg/mL solution containing 120mg/60mL							
	<table><tr><th>Form</th><th>Strength</th><th>Preparation</th></tr><tr><td>10mg/5mL</td><td>2mg/mL</td><td>Use TWELVE neat ampoules</td></tr></table>		Form	Strength	Preparation	10mg/5mL	2mg/mL	Use TWELVE neat ampoules
	Form	Strength	Preparation					
10mg/5mL	2mg/mL	Use TWELVE neat ampoules						
SC Injection								
Give required dose by SC injection								
Antidote	Continuous SC Infusion (Unlicensed)							
	Use 10mg per 2mL (5mg/mL) ampoule and dilute with WFI or sodium chloride 0.9%.							
Antidote	Flumazenil is a specific benzodiazepine antagonist and must be available to rapidly reverse respiratory depression when administering midazolam.							
Extravasation	Midazolam has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely. Re-site cannula at first signs of inflammation.							
Additional Information	<ul style="list-style-type: none">• Unlicensed for use in palliative care.• Administration via syringe driver is unlicensed and may increase the administration risk rating. To mitigate these risks:<ul style="list-style-type: none">○ Contact the Pharmacy Department or Palliative care team for further guidance.○ Consult the Palliative Care Formulary accessible on www.medicinescomplete.com or the Syringe Driver Survey Database (SDSD) (available after registration on www.palliativedrugs.com) for guidance on syringe driver compatibility.							

Information provided relates to Hypnovel® (Cheplapharm)

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542